- Teva Pharmaceutical Industries is Israel's largest pharmaceutical company and one of the world's leading generic drug manufacturers, with operations across approximately 60 countries and major manufacturing sites in Israel. - The BDS-1000 assessment rates Teva at 614 (Tier B - Severe Complicity), driven primarily by deep economic integration into the Israeli economy and institutional connections to state institutions. - The controlling-principal connection through Prof. Isaac Ben-Israel (former Head of IDF Military R&D who served on Teva's R&D Advisory Board 2003–2007) represents the strongest evidentiary basis for the score. - CEO Richard Francis issued a solidarity statement following the October 7 attacks, and approximately 10% of Teva's Israeli workforce was called to military reserve duty in Q3 2023. - Despite corporate political positioning with the IDF, the V-MIL score registers minimally (0.45) as no verified weapons procurement contracts were identified—only charitable medical supply donations through the "Adopt-a-Battalion" program.
Table of Contents
Teva Pharmaceutical Industries is Israel’s largest pharmaceutical company and one of the world’s leading generic drug manufacturers. Founded in Jerusalem in 1901, the company maintains its legal domicile, headquarters, and primary manufacturing operations within Israel’s pre-1967 borders. The BDS-1000 assessment identifies Teva as exhibiting severe complicity (Score 614, Tier B), driven primarily by the company’s deep structural integration into the Israeli economy and institutional alignment with Israeli state institutions.
The dominating complicity vector is V-ECON (Score 8.36), reflecting the company’s status as a foundational pillar of the Israeli economy—demonstrated by its TA-35 index membership, $750 million tax settlement with the Israel Tax Authority, and the advisory board tenure of Professor Isaac Ben-Israel, who served as Head of Military R&D at the Israel Defense Forces and Ministry of Defense from 1991–1997. This controlling-principal connection represents the strongest evidentiary basis for the score.
V-POL contributes meaningfully (Score 6.50) through CEO Richard Francis’s October 2023 solidarity statement following the October 7 attacks, the company’s IDF recognition for “exemplary” relations with reservist employees, and the call-up of approximately 10% of Teva’s Israeli workforce to military reserve duty.
In contrast, V-MIL (Score 0.45) and V-DIG (Score 0.34) register minimally. The V-MIL score reflects charitable medical supply donations to the IDF through the “Adopt-a-Battalion” program, but no verified weapons procurement contracts. The V-DIG score reflects Teva’s status as a technology customer (AWS cloud services, SAP ERP), not a provider to Israeli state agencies.
The composite score of 614 places Teva in Tier B, significant though below the most severe tier. The company’s pharmaceutical sector—which supplies medicines to civilian populations including in the Occupied Palestinian Territory—differentiates its profile from direct defence contractors.
| Date | Event |
|---|---|
| 1901 | Company founded in Jerusalem as Salomon, Levin, and Elstein Ltd. |
| 1935 | “Teva” trademark adopted (Hebrew for “nature”) |
| 2009 | IDF recognizes Teva for “exemplary” relationship with reservist employees |
| 2003–2007 | Prof. Isaac Ben-Israel serves on Teva’s R&D Advisory Board |
| October 11, 2023 | CEO Richard Francis issues solidarity statement following October 7 attacks |
| Q3 2023 | Approximately 10% of Teva’s Israeli workforce called to military reserve duty |
| 2024 | $750 million tax settlement reached with Israel Tax Authority |
| 2025 | Teva not included in UN OHCHR settlement database (158 companies listed) |
Teva Pharmaceutical Industries Ltd. is the world’s largest generic pharmaceutical manufacturer by volume, incorporated under the laws of the State of Israel and listed on both the New York Stock Exchange (TEVA) and Tel Aviv Stock Exchange (TA-35 index). The company operates globally across approximately 60 countries with a workforce of approximately 38,000 employees. Manufacturing facilities are concentrated in Israel, including sites in Kfar Saba (oral solid dosage), Netanya (R&D and specialty), Petah Tikva, and Ramat Hovav (active pharmaceutical ingredient manufacturing).
The company’s corporate structure includes Salomon, Levin & Elstein Ltd. (SLE), a wholly-owned distribution subsidiary that operates throughout Israel and the Occupied Palestinian Territory. Teva’s governance includes a Board of Directors with 11 members, all independent except CEO Richard Francis, and maintains relationships with Israeli institutions including the Israel Innovation Authority through the $10 million Rise open innovation program.
Financial highlights include a $4.25 billion settlement of US opioid litigation in 2022 and the $750 million 2024 tax settlement with the Israel Tax Authority covering “trapped earnings” from historical tax-exempt status under the Law for the Encouragement of Capital Investments (taxable years 2008–2020). Major institutional shareholders include BlackRock (5.59%), Harel Insurance (5.34%), and Phoenix Holdings (5.34%).
Teva Pharmaceuticals’ military-related activities consist primarily of charitable medical supply donations to the Israel Defense Forces, not formal defence procurement contracts. Following the October 7, 2023 attacks, Teva donated essential medicines, baby food compounds, and computers to the IDF through the “Adopt-a-Battalion” program, which enables corporate sponsorship of military units. CEO Richard Francis publicly stated that Teva is “the national pharmaceutical company of Israel” and posted solidarity with the Israeli flag 3.
The Thank Israeli Soldiers NGO acknowledged partnering with Teva Israel on corporate sponsorship activity 7. However, no public evidence has been identified of verified contracts, framework agreements, or memoranda of understanding between Teva and the Israeli Ministry of Defence, Israel Prison Service, or Israel Border Police beyond these documented charitable donations.
Teva Pharmaceuticals USA does hold contracts with the U.S. Department of Defense for adenovirus vaccines (delivery order SPE2DP25F4433 for $330,314 in March 2025), but these contracts involve the U.S. DoD as the end-user, not Israeli military or security agencies 6.
The absence of evidence regarding dual-use products is notable: no public evidence indicates that Teva manufactures ruggedised, tactical, mil-spec, or defence-grade pharmaceutical variants. Certain Teva generic products (atropine sulfate injection, morphine, epinephrine, ciprofloxacin, amoxicillin) are stocked by militaries globally as standard medical supplies, but these are standard-specification products available on the open civilian market, not purpose-built military variants.
Teva’s manufacturing capabilities—pharmaceutical API synthesis and finished-dose formulation—do not align with supply chain integration to defence primes. No evidence was identified of Teva supplying components, sub-systems, raw materials, or specialist manufacturing services to Elbit Systems, Israel Aerospace Industries, Rafael Advanced Defense Systems, or other Israeli defence contractors.
The scoring reflects this evidence structure: I=2.5 (charitable donations, no weapons supply), M=3.5 (isolated donations of unspecified scale), P=2.5 (corporate-level charitable engagement, not direct procurement). The resulting V-MIL score of 0.45 places Teva in the lowest band, reflecting negligible military-sector involvement beyond humanitarian medical donations.
The strongest counter-argument to this low V-MIL score would invoke the CEO’s public assertion that Teva is “the national pharmaceutical company of Israel” and the company’s participation in the IDF’s Adopt-a-Battalion program. Critics might argue that this corporate political positioning transcends charitable giving and indicates direct institutional alignment with the military establishment.
However, the evidentiary record does not support extending the score beyond charitable medical supply. The Adopt-a-Battalion program is a civilian corporate sponsorship initiative—distinct from formal procurement contracts under IDF framework agreements. No evidence documents Teva as a designated supplier to the Israeli Ministry of Defence for battlefield medical supply, field hospital equipment, or military pharmaceutical procurement.
Evidence gaps include: no disclosed contracts with IMOD for medical supply to field units, no documented pricing agreements or framework contracts with IDF medical corps, and no evidence of Teva participating in military hospital supply chains. The distinction between charitable giving and procurement is material to the scoring. Future evidence of verified IMOD contracts would substantially elevate the I and P criteria.
A further consideration: Teva’s generic pharmaceuticals supply the IDF medical corps as part of standard military medical supply chains, which may incidentally include pharmaceutical products purchased through Israeli government procurement. However, without documented contract evidence, this remains speculative rather than confirmed military procurement.
| Entity | Role/Relationship |
|---|---|
| Israel Defense Forces (IDF) | Recipient of charitable medical donations via Adopt-a-Battalion program |
| Thank Israeli Soldiers | NGO partner for corporate sponsorship activity |
| Richard Francis | CEO; publicly stated Teva is “the national pharmaceutical company of Israel” |
| Salomon, Levin & Elstein (SLE) | Wholly-owned distribution subsidiary; operates in OPT |
| U.S. Department of Defense | Client for adenovirus vaccine contracts (Teva USA) |
Teva Pharmaceuticals’ digital and technology profile reflects a pharmaceutical company’s typical operational technology infrastructure rather than any relationship with Israeli state cybersecurity, surveillance, or intelligence systems. The assessment identifies Teva definitively as a technology customer, not a provider.
Teva’s primary technology stack includes Amazon Web Services (AWS), selected as preferred cloud provider in December 2019 for a multi-year global engagement covering SAP workloads and core enterprise applications 11. This cloud infrastructure relationship positions AWS as Teva’s primary cloud partner. Teva operates SAP as its global ERP backbone, with over $10 million invested in SAP SuccessFactors to replace 30 local HR solutions across 80 countries.
No evidence was identified of licensing, subscription, or integration relationships with Israeli-founded or Israeli-headquartered technology vendors including Check Point Software, CyberArk, Wiz, SentinelOne, Claroty, NICE Systems, Verint Systems, or Palo Alto Networks. Teva does not publicly name any Israeli technology vendors in its technology stack.
Project Nimbus—the Israeli government’s national cloud contract awarded to Google Cloud and AWS in April 2021—is independent of Teva’s operations 12. While Teva, as an AWS customer with Israeli operations, may consume capacity from the AWS Israel region that physically overlaps Nimbus infrastructure, this remains unconfirmed and represents incidental geographic overlap rather than a contractual relationship.
In AI and machine learning, Teva is a consumer of cloud-based AI services via AWS and, historically, IBM Watson, applied internally to drug-discovery pipelines and manufacturing analytics. Teva is a founding partner of AION Labs, an AI-driven drug discovery venture studio (alongside AstraZeneca, Merck KGaA, Pfizer, and AWS), which is pharmaceutical research rather than AI systems provided to state bodies.
No evidence indicates Teva provides AI or algorithmic systems to Israeli state agencies, military units, or security services. The company’s digital capabilities remain confined to pharmaceutical R&D and supply-chain management.
This evidence structure supports the scoring: I=1.5 (incidental technology consumption as customer), M=4.5 (multi-year AWS engagement, SAP backbone represents significant investment), P=2.5 (standard commercial customer, no provider relationship to state). The V-DIG score of 0.34 reflects negligible direct digital involvement with Israeli state technology ecosystems.
The most significant challenge to the low V-DIG score would focus on potential indirect involvement: whether cloud infrastructure services consumed by Teva (AWS) might be the same infrastructure underlying Project Nimbus or other Israeli government digital systems. However, cloud infrastructure sharing is a fundamental characteristic of multi-tenant cloud services, and no evidence documents Teva receiving Israeli-origin technology components as part of its AWS engagement.
A second consideration: whether Teva’s Israeli R&D partnerships with Technion, Weizmann Institute, or Tel Aviv University involve co-development of dual-use or surveillance technology. The audit evidence confirms these partnerships focus on synthetic chemistry, drug formulation, biologics, and respiratory-device development—pharmaceutical research distinct from ICT or cybersecurity products.
Evidence gaps include: no public disclosure of systems integrators for AWS migration beyond AKT for SAP SuccessFactors, no confirmation of whether any integrator deployed Israeli-origin technology components, and no documented technology supply to Israeli state agencies. Teva’s digital health innovation partnerships (Rise platform with Israel Innovation Authority) focus on pharmaceutical applications, not surveillance technology.
The primary uncertainty involves the degree to which Teva’s AWS consumption may indirectly support Israeli government infrastructure through shared regional capacity. Without contractual disclosure or forensic analysis, this remains unconfirmed and does not meet the evidentiary threshold for elevated scoring.
| Entity | Role/Relationship |
|---|---|
| Amazon Web Services (AWS) | Primary cloud provider (customer relationship) |
| SAP | Global ERP backbone |
| AKT | Systems integrator for SAP SuccessFactors implementation |
| AION Labs | AI drug discovery venture studio; Teva as founding partner |
| Israel Innovation Authority | Partner in Rise open innovation platform ($10 million) |
The V-ECON domain constitutes the primary complicity vector for Teva Pharmaceuticals, generating the highest domain score (8.36) in the assessment. This reflects the company’s structural position as a foundational pillar of the Israeli economy, demonstrated through multiple lines of evidence.
Teva was founded in Jerusalem in 1901 and has maintained continuous Israeli domicile throughout its 120+ year history. The company’s headquarters remain in Petah Tikva, Israel, and it maintains major manufacturing facilities within Israel’s pre-1967 borders in Kfar Saba, Netanya, Jerusalem, and Ramat Hovav. Teva is Israel’s largest pharmaceutical company and one of the country’s largest private-sector employers, with approximately 38,000 global employees.
The controlling-principal evidence for elevated scoring centers on Professor Isaac Ben-Israel, who served on Teva’s R&D Advisory Board from 2003 to 2007. Prof. Ben-Israel previously served as Head of Military R&D at the Israel Defense Forces and Ministry of Defence from 1991 to 1997, and currently heads Tel Aviv University’s Blavatnik Interdisciplinary Cyber Research Center 4. This connection represents direct attributability between Teva’s governance and the Israeli defence establishment—an advisory board position constitutes a formal institutional relationship linking the company’s strategic R&D direction to a former senior defence official.
Teva’s economic integration extends to capital markets and taxation. The company is a constituent of the TA-35 Index on the Tel Aviv Stock Exchange, making it a core component of Israeli equity markets. The $750 million tax settlement with the Israel Tax Authority in 2024 (covering “trapped earnings” from historical tax-exempt status under Israel’s capital investment incentive programs for 2008–2020) demonstrates substantial economic flows inward to Israel from global operations 56. A prior settlement in 2012 involved approximately $718 million in trapped profits 11.
The company’s distribution subsidiary, Salomon, Levin & Elstein Ltd. (SLE), operates throughout Israel and the Occupied Palestinian Territory. Who Profits documents that SLE “enjoys easy access to the Palestinian market, free of customs and checkpoint” under the Paris Protocol economic arrangements, indicating commercial activity within markets of concern related to the occupation 12.
The scoring reflects this evidence structure: I=9.0 (extreme structural integration—Israeli domicile since 1901, HQ in Israel, Prof. Ben-Israel’s defence-establishment advisory board ties, TA-35 index, tax settlements), M=6.5 (moderate magnitude—major Israeli employer, strategic pharmaceutical sector, tax settlements), P=9.0 (very high proximity—direct ownership of Israeli operations, Israeli parent entity, profit repatriation). The V-ECON score of 8.36 represents the dominant complicity vector in the composite assessment.
The most substantial counter-argument to the high V-ECON score involves evidence that Teva is not included in the UN OHCHR settlement database (despite 2016–2019 discussions about potential inclusion). Critics might argue that the absence from this prominent list indicates reduced complicity. However, the OHCHR database focuses on businesses operating in Israeli settlements in the West Bank—Teva’s operations are primarily within Israel’s pre-1967 borders, which is a distinct geographic scope. The database’s absence does not negate Teva’s structural integration with the Israeli economy at the national level.
A second consideration involves the Prof. Ben-Israel advisory board connection. The tenure ended in 2007—approximately 18 years before the assessment period—so critics might argue this represents a historical connection insufficient for current scoring. However, advisory board relationships represent governance structures that shape institutional culture and professional networks. The scoring rationale notes that former senior defence officials serving on corporate advisory boards constitutes controlling-principal carry-through because the individual’s expertise, relationships, and institutional knowledge continue to inform company strategy.
Evidence gaps include: precise revenue contribution from Israeli operations (estimated at approximately 2% of global total but not precisely disclosed), the specific geographic scope of SLE’sOPT operations (warehousing or distribution points in West Bank settlements not confirmed), and whether Teva receives preferential treatment in Israeli government procurement beyond standard R&D tax incentives available to all qualifying Israeli companies.
The $750 million tax settlement might be framed as a dispute rather than evidence of ongoing privilege—but the settlement’s structure (covering trapped earnings from historical tax-exempt status) demonstrates that Teva’s Israeli operations benefited from substantial tax incentives, representing economic advantage derived from Israeli domicile.
| Entity | Role/Relationship |
|---|---|
| Prof. Isaac Ben-Israel | Former Head of IDF Military R&D (1991–1997); served on Teva R&D Advisory Board 2003–2007; currently heads Tel Aviv University Cyber Research Center |
| Salomon, Levin & Elstein (SLE) | Wholly-owned distribution subsidiary; operates in Israel and OPT |
| BlackRock | Major institutional shareholder (5.59%, 65M shares) |
| Harel Insurance | Major institutional shareholder (5.34%, 62M shares) |
| Phoenix Holdings | Major institutional shareholder (5.34%) |
| Israel Tax Authority | Counterparty to $750 million tax settlement (2024) |
| TA-35 Index | Teva is constituent of Tel Aviv Stock Exchange primary index |
The V-POL domain score (6.50) reflects Teva’s institutional alignment with Israeli state institutions, demonstrated through corporate communications, workforce integration, and partnership relationships.
CEO Richard Francis issued a public statement on October 11, 2023 expressing solidarity with Israel following the October 7 attacks, describing them as “unprecedented, horrific, and brutal attacks on Israeli civilians” 8. The statement made no reference to Palestinian civilian harm, called for no ceasefire, and expressed no humanitarian concern for Gaza. This selective framing demonstrates corporate political positioning alignment with the Israeli government’s narrative during the conflict.
Teva’s workforce integration with Israeli military institutions is documented: the IDF recognized Teva in 2009 for “exemplary” relationship with reservist employees, and in Q3 2023, approximately 10% of Teva’s Israeli workforce (roughly 338 employees) were called to military reserve duty. CEO Francis stated “our production remains unchanged” following the October 2023 mobilization, indicating organizational accommodation of military service obligations.
The company’s partnership with the Israel Innovation Authority through the Rise open innovation platform ($10 million budget, partnered with Startup Nation Central) represents ongoing institutional engagement with Israeli state economic development bodies continuing through 2025.
No public statements addressing Gaza, humanitarian access, or ceasefire were identified for the 2024–2025 period despite ongoing conflict. This contrasts with Teva’s March 2022 statement announcing an $11 million donation of essential medicines for Ukrainian refugees, demonstrating more substantial humanitarian engagement for Ukraine than for Gaza.
Teva has not issued public statements or changed operations following the ICJ advisory opinion (July 2024) or ICC arrest warrants (November 2024). The company’s ESG reports (Healthy Future) contain no reference to these legal proceedings.
The scoring reflects this evidence structure: I=6.5 (high institutional alignment—CEO statement, IDF recognition, workforce reserve duty), M=7.0 (moderate magnitude—sustained public alignment, ongoing Israeli operations, workforce integration, innovation partnerships), P=8.0 (moderate upper proximity—CEO statements as corporate acts, direct engagement with Israel Innovation Authority, Israeli-domiciled company decisions).
The Neutrality Floor applies given V-ECON≥5.0, ensuring V-POL≥2.0. The V-POL score of 6.50 represents meaningful political complicity through institutional alignment.
The strongest counter-argument involves the distinction between corporate statements and substantive political action. Critics might argue that CEO Francis’s October 2023 statement represents routine corporate expression of solidarity during a national crisis—comparable to statements from multinational corporations following any nation’s terrorist attack—rather than evidence of political alignment with the Israeli government’s specific policies.
However, the statement’s content matters: the omission of any reference to Palestinian civilian harm or humanitarian concern, during a conflict generating substantial international attention to civilian casualties, indicates selective framing. The contrast with Teva’s more expansive Ukrainian humanitarian response (2022) suggests the company evaluates humanitarian statements based on political context.
A second consideration: the IDF’s 2009 “exemplary” recognition occurred 15+ years before the assessment period and might represent historical rather than current institutional alignment. However, the recognition reflects documented relationship quality that contextualizes subsequent reserve duty call-ups and workforce integration.
Evidence gaps include: no documented corporate political contributions to Israeli political parties, no evidence of Teva participating in Israeli government “Brand Israel” public diplomacy campaigns, and no internal employee policy controversies or leaked communications regarding the Israel-Gaza conflict. The US federal lobbying disclosures (totaling $2.13 million in 2023, $2.25 million in 2024) address domestic healthcare policy—drug pricing, FDA matters—not foreign policy or Israel, which limits this as political complicity evidence.
The primary uncertainty involves whether Teva’s silence on ICJ/ICC proceedings represents deliberate positioning or simply reflects the company’s general practice of not offering political statements on international legal developments. Without explicit corporate communications, this remains interpretive rather than confirmed.
| Entity | Role/Relationship |
|---|---|
| Richard Francis | CEO; issued October 2023 solidarity statement |
| Rosemary Crane | Chairman of Board |
| IDF (Israel Defense Forces) | Recognized Teva in 2009 for “exemplary” reservist employee relations |
| Israel Innovation Authority | Partner in Rise open innovation platform with Teva |
| Teva Cares Foundation | US charitable foundation (501(c)(3)); $172.1 million charitable disbursements (2024) |
Several cross-cutting considerations merit attention. First, the BDS-1000 scoring distinguishes between sectors—a pharmaceutical company supplying medicines to civilian populations presents a fundamentally different complicity profile than a defence contractor supplying weapons systems. Teva’s generic medicines reach patients across the Occupied Palestinian Territory. Teva does not appear on the BDS movement’s primary consumer-boycott target list, though the BDS movement and Health Care Workers for Palestine have called for institutional boycotts of Teva. This sectoral consideration does not appear in the scoring algorithm but represents a relevant contextual factor.
Second, the V-MIL score might be challenged by arguing that pharmaceutical supply to military medical corps constitutes military involvement regardless of whether weapons are supplied. However, the rubric requires evidence of procurement contracts or formal supply agreements—charitable donations, while politically significant, do not meet this threshold. The scoring might change substantially if verified IMOD contracts emerge.
Third, the V-ECON score relies significantly on Prof. Ben-Israel’s advisory board tenure (2003–2007). While this connection is the strongest available governance evidence, the 18-year gap between advisory board service and the assessment period introduces temporal uncertainty about continued influence.
Fourth, institutional investor holdings (BlackRock, Harel Insurance, Phoenix Holdings) represent portfolio-level ownership in multiple Israeli companies, including Elbit Systems. These overlapping holdings demonstrate investment flow across Israeli corporations but represent passive ownership rather than Teva-specific complicity.
Fifth, the UN OHCHR settlement database absence might be misinterpreted as evidence of reduced complicity—though the database scope (settlement operations in West Bank) is distinct from national-level economic integration.
| Entity | Domain(s) | Role/Relationship |
|---|---|---|
| Israel Defense Forces (IDF) | V-MIL, V-POL | Recipient of charitable medical donations; recognized Teva for exemplary reservist relations |
| Thank Israeli Soldiers | V-MIL | NGO partner for corporate sponsorship activity |
| Salomon, Levin & Elstein (SLE) | V-ECON | Wholly-owned distribution subsidiary; operates in Israel and OPT |
| Prof. Isaac Ben-Israel | V-ECON | Former Head of IDF Military R&D; served on Teva R&D Advisory Board 2003–2007 |
| Richard Francis | V-POL | CEO; issued October 2023 solidarity statement |
| Amazon Web Services (AWS) | V-DIG | Primary cloud provider (customer relationship) |
| Israel Innovation Authority | V-POL | Partner in Rise open innovation platform |
| BlackRock | V-ECON | Major institutional shareholder (5.59%) |
| Harel Insurance | V-ECON | Major institutional shareholder (5.34%) |
| Phoenix Holdings | V-ECON | Major institutional shareholder (5.34%) |
| Israel Tax Authority | V-ECON | Counterparty to $750 million tax settlement |
| Domain | I | M | P | V-Score |
|---|---|---|---|---|
| V-MIL | 2.50 | 3.50 | 2.50 | 0.45 |
| V-DIG | 1.50 | 4.50 | 2.50 | 0.34 |
| V-ECON | 9.00 | 6.50 | 9.00 | 8.36 |
| V-POL | 6.50 | 7.00 | 8.00 | 6.50 |
The V-MIL score reflects charitable medical supply donations to the IDF through the Adopt-a-Battalion program, but no verified procurement contracts—the lowest band is appropriate given the absence of weapons or munition supply.
The V-DIG score reflects Teva’s status as a technology customer (AWS cloud, SAP ERP) rather than a provider to Israeli state agencies—no surveillance, cybersecurity, or state technology contracts documented.
The V-ECON score is the dominant complicity vector. The controlling-principal evidence (Prof. Ben-Israel’s defence establishment advisory board tenure) combined with structural domicile (founded 1901, HQ in Israel, TA-35 index constituent, $750M tax settlement) justifies I=9.0. The Israeli-Nexus Floor applies definitively.
The V-POL score reflects institutional alignment through CEO statements, IDF recognition, workforce reserve duty call-ups, and ongoing partnership with Israel Innovation Authority. The Neutrality Floor applies (V-ECON≥5.0 ensures V-POL≥2.0).
Composite score: BRS = 614 → Tier B (Severe Complicity).
Confidence levels: High confidence applies to the V-MIL and V-DIG scoring given clear evidentiary boundaries—Teva is definitively a pharmaceutical company without defence contracts or state technology provision. High confidence applies to V-ECON given the structural pillar evidence including Prof. Ben-Israel’s advisory board tenure and tax settlement documentation. High confidence applies to V-POL given documented statements, IDF recognition, and workforce integration evidence.
Evidence limits: The most significant limitation involves the Prof. Ben-Israel advisory board tenure—while this connection is confirmed, the 2003–2007 timeframe introduces questions about continued influence. Second, the precise revenue contribution from Israeli operations (estimated at approximately 2%) limits magnitude precision. Third, the geographic scope of SLE operations in the OPT lacks granular location data.
Open questions: Whether Teva holds undisclosed contracts with Israeli military or security agencies beyond documented donations; whether any systems integrator engaged by Teva deployed Israeli-origin technology components; whether future expansion into IDF procurement would alter the V-MIL score; the precise degree of Israeli government preferential treatment in standard procurement versus available incentive programs.
Given the BDS-1000 score of 614 (Tier B: Severe Complicity), the following actions are recommended:
For institutional investors:
– The V-ECON score (8.36) represents the primary complicity vector. Investors concerned about Israeli economic integration should note Teva’s structural position as a TA-35 index constituent and the tax settlement demonstrating significant economic flows to Israeli state coffers. The Prof. Ben-Israel advisory board connection represents governance-level attributability to the defence establishment.
– Norwegian Government Pension Fund Global (NBIM) maintains investment in Teva as of June 2025—divestment decisions should weigh the V-ECON evidence against the company’s sector (pharmaceuticals serving civilian populations).
For civil society:
– The V-MIL evidence (charitable donations, not procurement contracts) indicates Teva is not a direct defence contractor—boycott efforts focused on Teva should distinguish between pharmaceutical supply (which serves Palestinian patients) and weapons supply.
– Teva does not appear on the BDS movement’s primary consumer-boycott target list, though the BDS movement and Health Care Workers for Palestine have called for institutional boycotts of Teva—reflecting the complexity of pharmaceutical sector complicity.
For corporate engagement:
– Teva could materially alter its V-POL score by issuing public statements acknowledging humanitarian concerns in Gaza, or by responding to ICJ/ICC proceedings—the current silence contributes to institutional alignment perception.
– Enhanced disclosure of geographic revenue breakdown and OPT operations would improve assessment precision.
For continued monitoring:
– Any verified emergence of formal IMOD or IDF procurement contracts would substantially elevate V-MIL scoring.
– The 2025 UN OHCHR database update remained unchanged from prior versions—future updates should be monitored for potential Teva inclusion if settlement-operation evidence emerges.
Who Profits Research Center — https://www.whoprofits.org/companies/company/4212 ↩
Who Profits Research Center (SLE subsidiary) — https://www.whoprofits.org/companies/company/4243 ↩
Stop Teva report on IDF involvement — https://stopteva.nl/wp-content/uploads/2025/07/20250615_Teva_and_the_IDF_Repill-.pdf ↩
Tel Aviv University profile on Prof. Ben-Israel — https://english.tau.ac.il/profile/itzik ↩
Teva press release on Israel Tax Authority settlement — https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2024/Teva-Reaches-Agreement-With-the-Israel-Tax-Authority ↩
Reuters report on $750 million tax settlement — https://www.reuters.com/business/healthcare-pharmaceuticals/teva-settles-tax-dispute-israel-with-750-mln-payment-2024-06-25 ↩↩
Thank Israeli Soldiers Facebook post — https://www.facebook.com/ThankIsraeliSoldiers/posts/we-were-honored-to-partner-with-teva_israel_-teva-pharmaceuticals-on-a-beautiful/1032698839045059 ↩
Teva CEO statement on October 2023 situation — https://www.tevapharm.com/news-and-media/latest-news/teva-statement-on-the-situation-in-israel/ ↩
Reuters report on Q3 2023 reserve duty — https://www.reuters.com/business/healthcare-pharmaceuticals/teva-pharm-q3-profit-rises-sees-higher-2023-revenue-2023-11-08 ↩
Wikipedia entry on Teva Pharmaceuticals — https://en.wikipedia.org/wiki/Teva_Pharmaceuticals ↩
Wall Street Journal report on 2012 tax settlement — https://www.wsj.com/articles/SB10001424052702303460004579191940528610628 ↩↩
The Intercept report on Project Nimbus — https://theintercept.com/2024/05/01/google-amazon-nimbus-israel-weapons-arms-gaza ↩
Teva Russia Ukraine update — https://www.tevapharm.com/news-and-media/teva-russia-update ↩
Teva Rise healthcare innovation program — https://www.tevapharm.com/news-and-media/feature-stories/teva-rise-healthcare-innovation-and-technology ↩
Ynet News report on Rise program — https://www.ynetnews.com/business/article/ryambdhxwg ↩
Declassified UK report on IDF relationship — https://www.declassifieduk.org/the-israeli-firm-aiding-the-nhs-and-idf ↩
